According to Zacks, “Electromed, Inc. manufactures, markets and sells products that provide airway clearance therapy to patients with compromised pulmonary function. The Company is the designer, manufacturer and worldwide provider of the SmartVest® Airway Clearance System and related products. The patented system uses High Frequency Chest Wall Oscillation (HFCWO), an alternative to Chest Physiotherapy (CPT), to deliver airway clearance treatment. The Company manufactures its products for use by chronically-ill patients who face health risks due to pneumonia and mucus accumulation in the lungs, particularly patients with cystic fibrosis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and neuro-muscular disorders. The purpose of its primary product, the SmartVest System, is to loosen, mobilize, and release respiratory secretions from the lungs. The Company’s products are primarily used in the home health care market and in hospitals. Electromed, Inc. is headquartered in New Prague, Minnesota. “
Separately, TheStreet upgraded Electromed from a hold rating to a buy rating in a research report on Friday, September 16th.
Shares of Electromed (NYSEMKT:ELMD) opened at 4.65 on Thursday. The stock’s 50 day moving average is $4.81 and its 200 day moving average is $4.40. Electromed has a 52-week low of $1.55 and a 52-week high of $6.26. The company has a market cap of $38.21 million, a PE ratio of 17.22 and a beta of 0.89.
Electromed (NYSEMKT:ELMD) last posted its quarterly earnings data on Tuesday, September 6th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.05 by $0.01. The firm had revenue of $5.70 million for the quarter. Equities analysts forecast that Electromed will post $0.19 EPS for the current year.
Large investors have recently added to or reduced their stakes in the company. Acrospire Investment Management LLC acquired a new position in shares of Electromed during the first quarter worth about $135,000. Renaissance Technologies LLC acquired a new position in shares of Electromed during the first quarter worth about $401,000. Alambic Investment Management L.P. raised its position in shares of Electromed by 28.0% in the second quarter. Alambic Investment Management L.P. now owns 29,571 shares of the company’s stock worth $114,000 after buying an additional 6,474 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Electromed by 121.3% in the second quarter. Dimensional Fund Advisors LP now owns 81,724 shares of the company’s stock worth $315,000 after buying an additional 44,795 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Electromed by 12.3% in the second quarter. Vanguard Group Inc. now owns 81,929 shares of the company’s stock worth $316,000 after buying an additional 8,997 shares during the period.
Electromed Company Profile
Electromed, Inc, is a pharmaceutical company. The Company manufactures, markets and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System (SmartVest System) includes its newest generation SmartVest SQL and previous generation SV2100 and related products, to patients with compromised pulmonary function.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Electromed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electromed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.